GP和TP方案治疗晚期非小细胞肺癌的临床观察  

Clinical study of chemotherapy in advanced non-small cell lung cancer with cisplatin combined with gemcitabine or docetaxel respectively

作　　者：孙安平[1] 李燕红[1] 雍文穆[1] 张霞[1] 

机构地区：[1]陕西省汉中市中心医院呼吸科,陕西汉中723000

出　　处：《现代肿瘤医学》2009年第6期1074-1076,共3页Journal of Modern Oncology

摘　　要：目的:观察吉西他滨或多西他赛联合顺铂方案(GP方案/TP方案)治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效和毒副作用。方法:140例晚期NSCLC患者随机分成两组分别接受GP方案和TP方案进行全身静脉化疗,每例患者至少接受2个周期以上的同一方案治疗,比较两组方案治疗的近期疗效、不良反应及1年生存期。结果:GP组和TP组的总有效率分别为48.6%和47.1%:1年生存率分别为43.8%和41.7%;中位生存期分别为11.3个月和10.7个月,两组间比较差异无统计学意义(P>0.05)。GP组和TP组的不良反应均在可耐受范围。结论:GP方案与TP方案对初治晚期非小细胞肺癌疗效确切,可作为晚期初治NSCLC的一线化疗方案。Objective：To evaluate the effect and toxicity of chemotherapy in advanced non - small cell lung cancer （NSCLC） with cisplatin combined with gemcitabine or docetaxel respectively. Methods： A total of 140 patients with advanced NSCLC were randomized into two groups： one group （70 cases） were treated with Gemcitabine and Cisplatin （GP group）, and the other group （70 cases） were treated with Docetaxel and Cisplatin （TP group）, repeated every 21 days. Each patient was received 2 cycles＇chemotherapy at least. The short - term effect, side effects, median survival time and 1 - year survival rate were evaluated after chemotherapy. Results： The short - term response rates in GP group and TP group were 48.6% and 47.1% respectively, 1 - year survival rates were 43.8% and 41.7%, and the median survival time was 11.3 months and 10.7 months, respectively. No significant difference was observed between the two groups （ P 〉 0.05 ）. Conclusion： The regimen of GP and TP can be considered as first line chemotherapy in advanced NSCLC for their conclusive and similar curative effect.

关 键 词：非小细胞肺癌 化疗 吉西他滨 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤]